Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8137992 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(a month from now) | |
US8137994 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(a month from now) | |
US8137993 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(a month from now) | |
US7888310 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy |
Jul, 2023
(a month from now) | |
US9895422 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(7 years from now) | |
US9352025 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(7 years from now) | |
US10688155 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(7 years from now) | |
US8877708 | VEROSCIENCE | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
Jun, 2030
(7 years from now) | |
US8613947 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
US9700555 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
US9993474 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
US9192576 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
US9522117 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
US10688094 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
US11000522 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
US8431155 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) |
Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient
Market Authorisation Date: 05 May, 2009
Treatment: Improvements of glycemic control in individuals with type 2 diabetes who have one or more specified cardiovascular risk factors; Adjunct to diet and exercise to improve glycemic control in adults with...
Dosage: TABLET;ORAL
24
United States
5
European Union
4
Australia
3
Spain
3
Japan
2
Mexico
2
Brazil
1
Canada
1
Argentina
1
China
1
Uruguay
1
Korea, Republic of
1
Hong Kong
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic